-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
FY2022 Earnings Forecast for Allogene Therapeutics, Inc. (NASDAQ:ALLO) Issued By HC Wainwright
FY2022 Earnings Forecast for Allogene Therapeutics, Inc. (NASDAQ:ALLO) Issued By HC Wainwright
Allogene Therapeutics, Inc. (NASDAQ:ALLO) – Investment analysts at HC Wainwright lifted their FY2022 earnings estimates for Allogene Therapeutics in a report issued on Monday, November 21st. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($2.44) per share for the year, up from their previous estimate of ($2.46). HC Wainwright has a "Buy" rating and a $29.00 price target on the stock. The consensus estimate for Allogene Therapeutics' current full-year earnings is ($2.38) per share. HC Wainwright also issued estimates for Allogene Therapeutics' Q4 2022 earnings at ($0.77) EPS and FY2023 earnings at ($3.00) EPS.
Get Allogene Therapeutics alerts:
A number of other research firms have also recently weighed in on ALLO. JMP Securities reiterated a "buy" rating and set a $23.00 price objective on shares of Allogene Therapeutics in a research report on Tuesday, September 27th. Oppenheimer cut their price objective on shares of Allogene Therapeutics to $32.00 in a research report on Thursday, October 13th. Truist Financial cut their price objective on shares of Allogene Therapeutics to $29.00 in a research report on Tuesday, August 23rd. Raymond James cut shares of Allogene Therapeutics from an "outperform" rating to a "market perform" rating in a report on Wednesday, August 10th. Finally, B. Riley cut their price target on shares of Allogene Therapeutics from $21.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, September 22nd. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $25.70.
Allogene Therapeutics Stock Down 0.9 %
ALLO stock opened at $10.60 on Wednesday. Allogene Therapeutics has a twelve month low of $6.43 and a twelve month high of $19.25. The stock has a market capitalization of $1.53 billion, a price-to-earnings ratio of -4.82 and a beta of 0.59. The firm's fifty day simple moving average is $10.57 and its two-hundred day simple moving average is $11.43.
Allogene Therapeutics (NASDAQ:ALLO – Get Rating) last announced its quarterly earnings results on Wednesday, November 2nd. The company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.04. Allogene Therapeutics had a negative net margin of 126,580.16% and a negative return on equity of 37.74%. During the same period in the previous year, the firm earned ($0.57) EPS.
Institutional Trading of Allogene Therapeutics
A number of hedge funds have recently added to or reduced their stakes in ALLO. Woodline Partners LP lifted its stake in Allogene Therapeutics by 1,255.9% in the second quarter. Woodline Partners LP now owns 5,859,679 shares of the company's stock worth $66,800,000 after acquiring an additional 5,427,529 shares during the period. State Street Corp lifted its stake in Allogene Therapeutics by 78.5% in the first quarter. State Street Corp now owns 7,877,648 shares of the company's stock worth $71,765,000 after acquiring an additional 3,464,603 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in Allogene Therapeutics by 30.3% in the second quarter. Price T Rowe Associates Inc. MD now owns 5,559,176 shares of the company's stock worth $63,375,000 after acquiring an additional 1,292,441 shares during the period. Goldman Sachs Group Inc. lifted its stake in Allogene Therapeutics by 62.5% in the first quarter. Goldman Sachs Group Inc. now owns 2,962,209 shares of the company's stock worth $26,986,000 after acquiring an additional 1,138,944 shares during the period. Finally, Renaissance Technologies LLC purchased a new stake in Allogene Therapeutics in the first quarter worth about $8,880,000. 84.81% of the stock is owned by hedge funds and other institutional investors.
About Allogene Therapeutics
(Get Rating)
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL.
Read More
Get a free copy of the StockNews.com research report on Allogene Therapeutics (ALLO)
Institutional Support for Analog Devices Remains High
Microsoft Shares: Is it Time to Back Up the Truck?
Is the 60/40 Portfolio Mix Still in Vogue?
Three CBD Stocks to Dominate a Budding Industry
Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Allogene Therapeutics, Inc. (NASDAQ:ALLO) - HC Wainwright的投资分析师在11月21日星期一发布的报告中提高了对Allogene Therapeutics的2022财年盈利预测。HC Wainwright分析师R.Burns现在预测,该公司今年的每股收益将为2.44美元,高于此前预测的2.46美元。HC Wainwright对该股的评级为买入,目标价为29.00美元。对异种基因治疗公司目前全年收益的普遍估计为每股2.38美元。HC Wainwright还发布了对异基因治疗公司2022年第四季度每股收益(0.77美元)和2023财年每股收益(3.00美元)的估计。
到达同种异体基因治疗警报:
其他一些研究公司最近也加入了对Allo的研究。JMP证券在9月27日(星期二)的一份研究报告中重申了“买入”评级,并为异体基因治疗公司的股票设定了23.00美元的目标价。奥本海默在10月13日星期四的一份研究报告中将他们对异基因治疗公司股票的目标价下调至32.00美元。在8月23日星期二的一份研究报告中,Truist Financial将他们对异基因治疗公司股票的目标价下调至29.00美元。雷蒙德·詹姆斯在8月10日星期三的一份报告中将异基因治疗公司的股票评级从“跑赢大盘”下调至“市场表现”。最后,B.Riley在9月22日星期四的一份报告中将allgene治疗公司的股票目标价从21.00美元下调至18.00美元,并对该股设定了“买入”评级。两名股票研究分析师对该股的评级为持有,七名分析师对该公司股票的评级为买入。根据MarketBeat的数据,该公司目前的平均评级为“中等买入”,平均目标价为25.70美元。
同种基因治疗类股下跌0.9%
Allo股价周三开盘报10.60美元。异基因治疗公司的12个月低点为6.43美元,12个月高位为19.25美元。该股市值15.3亿美元,市盈率为-4.82,贝塔系数为0.59。该公司的50日简单移动均线为10.57美元,200日简单移动均线为11.43美元。
异基因治疗公司(纳斯达克:ALLO-GET评级)上一次公布季度收益是在11月2日星期三。该公司公布了本季度每股收益(0.58美元),比普遍预期的(0.62美元)高出0.04美元。同种基因治疗公司的净利润率为负126580.16%,净资产回报率为负37.74%。去年同期,该公司每股收益为0.57美元。
同种异体基因治疗药物的制度性交易
多家对冲基金最近增持或减持了Allo的股份。Woodline Partners LP在第二季度增持了1,255.9%的allgene Treateutics股份。在此期间,Woodline Partners LP增持了5,427,529股,目前持有该公司5,859,679股股票,价值66,800,000美元。道富集团在第一季度增持了78.5%的allgene Treateutics股份。道富银行目前持有该公司7,877,648股股票,价值71,765,000美元,在此期间又收购了3,464,603股。Price T Rowe Associates Inc.MD在第二季度将其在allgene Treateutics的持股比例提高了30.3%。Price T Rowe Associates Inc.MD在此期间额外收购了1,292,441股后,目前拥有5,559,176股该公司股票,价值63,375,000美元。高盛股份有限公司在第一季度增持了异基因治疗公司62.5%的股份。高盛股份有限公司在此期间增持了1,138,944股,目前持有该公司2,962,209股股票,价值26,986,000美元。最后,文艺复兴技术有限责任公司在第一季度购买了异种基因治疗公司的新股份,价值约888万美元。84.81%的股票由对冲基金和其他机构投资者持有。
关于同种异体基因疗法
(获取评级)
异体基因治疗公司是一家临床阶段免疫肿瘤学公司,开发并商业化用于癌症治疗的基因工程同种异体T细胞疗法。它开发、制造和商业化UCART19,这是一种同种异体嵌合抗原受体(CAR)T细胞产品,用于治疗R/R CD19阳性B细胞ALL的儿童和成人患者。
阅读更多内容
免费获取StockNews.com关于同种异体基因治疗的研究报告(ALLO)
机构对ADI的支持仍然很高
微软股票:是时候备份卡车了吗?
60/40的投资组合组合还在《时尚》杂志上流行吗?
三只CBD股票将主宰一个萌芽行业
Salesforce裁员,尽管面临挑战,但收入强劲
接受《同种异体基因治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯,接收最新新闻和分析师对异种基因治疗公司和相关公司评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧